{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T08:04:58Z","timestamp":1750061098669,"version":"3.40.5"},"reference-count":48,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEOR"],"DOI":"10.2147\/ceor.s471855","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T04:20:18Z","timestamp":1727497218000},"page":"721-731","source":"Crossref","is-referenced-by-count":1,"title":["Consideration for Health Disparities in Value Assessment Frameworks"],"prefix":"10.2147","volume":"Volume 16","author":[{"given":"Dominique","family":"Seo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divya","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4491-7139","authenticated-orcid":true,"given":"Joe","family":"Vandigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7786-5780","authenticated-orcid":true,"suffix":"II","given":"T","family":"Mattingly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.2105\/AJPH.2018.304931","volume":"109","author":"Duran","year":"2019","journal-title":"Ame J Pub Health"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"e013620","DOI":"10.1136\/bmjopen-2016-013620","volume":"7","author":"Ndugga","year":"2017","journal-title":"BMJ Open"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"Sanders","year":"2016","journal-title":"J Ame Med Ass"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jval.2021.07.005","volume":"25","author":"Zhang","year":"2022","journal-title":"Value Health"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jval.2017.12.012","volume":"21","author":"Neumann","year":"2018","journal-title":"Value Health"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jval.2016.11.027","volume":"20","author":"Cookson","year":"2017","journal-title":"Value Health"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jval.2017.12.009","volume":"21","author":"Garrison","year":"2018","journal-title":"Value Health"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.18553\/jmcp.2021.27.9-a.s22","volume":"27","author":"Diaby","year":"2021","journal-title":"J Managed Care Specialty Pharm"},{"key":"ref9","unstructured":"Review ICER. 2020-2023 Value assessment framework; 2020."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.18553\/jmcp.2020.26.9.1162","volume":"26","author":"Thokala","year":"2020","journal-title":"J Managed Care Spec Pharm"},{"key":"ref11","first-page":"9","volume":"9","author":"Pizzi","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"ref12","unstructured":"Review ICER. ICER launches initiative to evaluate and advance health technology assessment methods that support health equity; 2022."},{"key":"ref13","first-page":"136","volume":"13","author":"Gerlach","year":"2020","journal-title":"Ame Health Drug Benefits"},{"key":"ref14","unstructured":"Review ICER. History & Impact; 2022."},{"volume-title":"Ethical and Distributive Considerations","year":"2016","key":"ref15"},{"key":"ref16","unstructured":"ICON. ICER\u2019s impact on payer decision making: results of icon\u2019s third annual survey; 2020."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2105\/AJPH.2018.304883","volume":"109","author":"Alvidrez","year":"2019","journal-title":"Am J Public Health"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.18865\/ed.25.3.245","volume":"25","author":"Hill","year":"2015","journal-title":"Ethnic Dis"},{"volume-title":"Toward an Experimental Ecology of Human Development. American Psychologist","year":"1977","key":"ref19"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1471-2288-13-117","volume":"13","author":"Gale","year":"2013","journal-title":"BMC Med Res Method"},{"volume-title":"The Coding Manual for Qualitative Researchers","year":"2021","key":"ref21"},{"key":"ref22","unstructured":"Review ICER. Aducanumab for Alzheimer\u2019s disease: effectiveness and value; 2021."},{"key":"ref23","unstructured":"Review ICER. Anti B-cell maturation antigen car T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma; 2021."},{"key":"ref24","unstructured":"Review ICER. Belimumab and voclosporin for lupus nephritis: effectiveness and value; 2021."},{"key":"ref25","unstructured":"Review ICER. Bempedoic acid and inclisiran for patients with heterozygous familial hypercholesterolemia and for secondary prevention of ASCVD: effectiveness and value; 2021."},{"key":"ref26","unstructured":"Review ICER. Betibeglogene autotemcel for beta thalassemia: effectiveness and value; 2022."},{"key":"ref27","unstructured":"Review ICER. Crizanlizumab, voxelotor, and l-glutamine for sickle cell disease: effectiveness and value; 2021."},{"key":"ref28","unstructured":"Review ICER. Dupilumab and crisaborole for atopic dermatitis: effectiveness and value; 2017."},{"key":"ref29","unstructured":"Review ICER. Eculizumab and efgartigimod for the treatment of myasthenia gravis: effectiveness and value; 2021."},{"key":"ref30","unstructured":"Review ICER. JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis response to public comments on draft evidence report; 2021."},{"key":"ref31","unstructured":"Review ICER. Mavacamten for hypertrophic cardiomyopathy: effectiveness and value; 2021."},{"key":"ref32","unstructured":"Review ICER. Modulator treatments for cystic fibrosis: effectiveness and value; 2020."},{"key":"ref33","unstructured":"Review ICER. Nadofaragene firadenovec and oportuzumab monatox for bcg-unresponsive, non-muscle invasive bladder cancer: effectiveness and value; 2021."},{"key":"ref34","unstructured":"Review ICER. Novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects; 2022."},{"key":"ref35","unstructured":"Review ICER. Obeticholic acid for the treatment of nonalcoholic steatohepatitis with fibrosis; 2020."},{"key":"ref36","unstructured":"Review ICER. Targeted immune modulators for ulcerative colitis: effectiveness and value; 2020."},{"key":"ref37","unstructured":"Review ICER. Tezepelumab for severe asthma; 2021."},{"key":"ref38","unstructured":"Review ICER. Tirzepatide for type 2 diabetes; 2022."},{"key":"ref39","unstructured":"Review ICER. Treatments for anemia in chronic kidney disease: effectiveness and value; 2021."},{"key":"ref40","unstructured":"Review ICER. Valoctocogene roxaparvovec and emicizumab for hemophilia a without inhibitors: effectiveness and value; 2020."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.18553\/jmcp.2021.27.11.1601","volume":"27","author":"Ronquest","year":"2021","journal-title":"J Managed Care Spec Pharm"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jval.2021.01.006","volume":"24","author":"Bloudek","year":"2021","journal-title":"Value Health"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jval.2020.01.011","volume":"23","author":"Trenaman","year":"2020","journal-title":"Value Health"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12913-020-4974-4","volume":"20","author":"Cloutier","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3111\/13696998.2015.1016228","volume":"18","author":"Zhou","year":"2015","journal-title":"J Med Eco"},{"key":"ref46","unstructured":"National Eczema Association and Asthma and Allergy Foundation of America Comment Letter to ICER. Asthma and allergy foundation of America; 2021."},{"key":"ref47","unstructured":"Review ICER. ICER review of ad treatments: feedback on draft evidence review & voting questions; 2021."},{"key":"ref48","unstructured":"Review ICER. JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value; 2021."}],"container-title":["ClinicoEconomics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/96009","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/96009","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T04:20:33Z","timestamp":1727497233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/consideration-for-health-disparities-in-value-assessment-frameworks-peer-reviewed-fulltext-article-CEOR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":48,"URL":"https:\/\/doi.org\/10.2147\/ceor.s471855","relation":{},"ISSN":["1178-6981"],"issn-type":[{"type":"electronic","value":"1178-6981"}],"subject":[],"published":{"date-parts":[[2024,9]]}}}